Inventor · disambiguated record
Mark Renshaw
Also filed as: RENSHAW MARK
9 granted patents·13 pending applications·201 citations·filing 2001–2023
87Inventor score
Files withALEXION PHARMA INC6BOWDISH KATHERINE S3PROCISEDX INC3PROMETHEUS BIOSCIENCES INC3ANAPHORE INC2
Top patents by PatentIndex Score
22 records- 0193US7396917B2Rationally designed antibodiesALEXION PHARMA INC·Filed 2002·Granted Jul 8, 2008·46 cites·65 claims
- 0293US7306906B2Engineered templates and their use in single primer amplificationALEXION PHARMA INC·Filed 2002·Granted Dec 11, 2007·123 cites·28 claims
- 0389US11866505B2Anti-CD30L antibodies and uses thereofPROMETHEUS BIOSCIENCES INC·Filed 2022·Granted Jan 9, 2024·1 cites·30 claims
- 0487US7482435B2Rationally designed antibodiesALEXION PHARMA INC·Filed 2001·Granted Jan 27, 2009·20 cites·53 claims
- 0583US7414111B2Engineered templates and their use in single primer amplificationALEXION PHARMA INC·Filed 2003·Granted Aug 19, 2008·10 cites·2 claims
- 0681US8771932B2Rationally designed antibodiesBOWDISH KATHERINE S·Filed 2009·Granted Jul 8, 2014·1 cites·20 claims
- 0768US2024254246A1Anti-cd30l antibodies and uses thereofPROMETHEUS BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 0865US9409964B2Rationally designed antibodiesALEXION PHARMA INC·Filed 2014·Granted Aug 9, 2016·0 cites·13 claims
- 0963US8674082B2Rationally designed antibodiesBOWDISH KATHERINE S·Filed 2008·Granted Mar 18, 2014·0 cites·35 claims
- 1062US2025340660A1Anti-cd30l antibodies, formulations therefor, and uses thereofPROMETHEUS BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 1158US2019271711A1Processing reagent and use thereof in assays for detection of analytes associated with a binding proteinQUIDEL CORP·Filed 2019·Application pending·0 cites
- 1257US2010105620A1Polypeptides that bind Trail-R1 and Trail-R2ANAPHORE INC·Filed 2009·Application pending·0 cites
- 1356US10338084B2Processing reagent and use thereof in assays for detection of analytes associated with a binding proteinQUIDEL CORP·Filed 2017·Granted Jul 2, 2019·0 cites·9 claims
- 1455US2009011471A1Engineered plasmids and their use for in situ production of genesALEXION PHARMA INC·Filed 2007·Application pending·0 cites
- 1551US2004253242A1Rationally designed antibodiesFiled 2003·Application pending·0 cites
- 1650US2003049731A1Engineered plasmids and their use for in situ production of genesFiled 2001·Application pending·0 cites
- 1749US2022137035A1DETECTION OF HEMOGLOBIN A1C (HbA1c) IN BLOODPROCISEDX INC·Filed 2021·Application pending·0 cites
- 1847US2023160906A1Detection of anti-tnf alpha drug biologics and anti-drug antibodiesPROCISEDX INC·Filed 2021·Application pending·0 cites
- 1946US2022146501A1Assay methods for the detection of human serum albumin, vitamin d, c-reactive protein, and anti-transglutaminase autoantibodyPROCISEDX INC·Filed 2021·Application pending·0 cites
- 2045US2012135938A1Polypeptides that Bind TRAIL-R1 and TRAIL-R2BOWDISH KATHERINE S·Filed 2012·Application pending·0 cites
- 2140US2012021995A1Polypeptides that Bind TRAIL-R1 and TRAIL-R2BOWDISH KATHERINE·Filed 2011·Application pending·0 cites
- 2233US2011086770A1Combinatorial Libraries Based on C-type Lectin-like DomainANAPHORE INC·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mark Renshaw files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →